Last deal

Amount

Convertible Note

Stage

17.05.2023

Date

3

all rounds

$120M

Total amount

date founded

Financing round

General

About Company
Scribe Therapeutics is a biotech company that develops gene-editing therapies using CRISPR-CasX technology.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Convertible Note

IPO status

Private

Description

The company, founded in 2018 by a group of genome and molecular engineers, focuses on developing X-Editing (XE) molecules that improve upon existing CRISPR genome editing technology. Their treatments target neurodegenerative disorders and can be applied both inside and outside the body. Scribe Therapeutics aims to treat a wide range of diseases, including neurological, ophthalmological, multisystem, muscle, and metabolic disorders, as well as hematopoietic disorders and cell therapy. The company has secured significant funding, including a $20 million series A financing round led by Andreessen Horowitz and a $100 million series B financing round led by Avoro Ventures and Avoro Capital Advisors. Scribe Therapeutics has also entered into a research partnership with Biogen Inc. and has expanded its board of directors.
Contacts

Contact Email

Social url

Similar Companies
1000
Intellia Therapeutics

Intellia Therapeutics

Intellia Therapeutics is a biotechnology company that uses genetic engineering to develop medical therapies for severe diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Health Care

Location

Cambridge, MA, USA

total rounds

7

total raised

$1.54B

count Of Investments

2
Refuge Biotechnologies

Refuge Biotechnologies

The company Refuge Biotechnologies focuses on gene editing and genetic engineering of immune cells for cancer immunotherapy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Menlo Park, CA, USA

total rounds

2

total raised

$33.9M
Shape Therapeutics

Shape Therapeutics

Shape Therapeutics is a biotech company that develops RNA technologies for gene therapy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Therapeutics

Location

Seattle, WA, USA
Avidity Biosciences

Avidity Biosciences

Avidity Biosciences is a biotech company developing oligonucleotide-based therapies to treat serious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

9

total raised

$1.49B

Financials

Funding Rounds
3
3

Number of Funding Rounds

$120M

Money Raised

Their latest funding was raised on 17.05.2023. Their latest investor Prevail Therapeutics. Their latest round Convertible Note

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Prevail Therapeutics

Prevail Therapeutics

Prevail Therapeutics is a biotech company that develops gene therapies for Parkinson’s disease and other neurodegenerative diseases..

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Therapeutics

Location

New York, NY, USA

total rounds

3

total raised

$129M

count Of Investments

1
Avoro Capital Advisors

Avoro Capital Advisors

Avoro Capital Advisors is a global life sciences investment firm that supports emerging biotechnology companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Financial Services, Venture Capital

Location

New York, NY, USA

count Of Investments

16

count Of Exists

2

Avoro Ventures

Avoro Ventures is a biopharma venture fund manager.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Biotechnology, Financial Services

count Of Investments

4
Andreessen Horowitz

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm that invests in technology companies at various stages of development.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Software, Venture Capital

Location

Menlo Park, CA, USA

count Of Investments

1188

count Of Exists

153
Co-Investors
Investors
10
4

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Convertible Note
Yes
Series A, Series B
No
Series B
Prevail Therapeutics

Prevail Therapeutics

Prevail Therapeutics is a biotech company that develops gene therapies for Parkinson’s disease and other neurodegenerative diseases..

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Therapeutics

Location

New York, NY, USA

total rounds

3

total raised

$129M

count Of Investments

1
Andreessen Horowitz

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm that invests in technology companies at various stages of development.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Software, Venture Capital

Location

Menlo Park, CA, USA

count Of Investments

1188

count Of Exists

153
Vijay Pande

Vijay Pande

Vijay Pande, PhD, is a general partner at Andreessen Horowitz, where he focuses on investments in biopharma and healthcare, and serves on the boards of Apeel Sciences, Asimov, BioAge, Ciitizen, Devoted Health, Freenome, Insitro, Omada, PatientPing, and Rigetti Computing. Pande is also an Adjunct Professor of Bioengineering at Stanford University, where he continues to advise the Pande Lab, focused on tackling challenging problems in chemical biology, biophysics, and biomedicine. As the founding investor of a16z’s Bio Fund, Pande leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. Op-eds by Pande defining trends and issues in this emerging space have been published by The New York Times, Scientific American, and Forbes, among others. Previously, Pande was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications, two patents, and two novel drug candidates). Pande was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country. During his time at Stanford, Pande co-founded Globavir Biosciences, where he translated his research advances into a successful startup that aimed to discover cures for Dengue Fever and Ebola. Pande also founded the Folding@Home Distributed Computing Project for disease research, which pushed the boundaries of computer science techniques (distributed systems, machine learning, and exotic computer architectures) into biology and medicine, in both research as well as the development of new therapeutics. Pande holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation; a Guinness World Record for Folding@Home; the American Chemical Society Thomas Kuhn Paradigm Shift Award; and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog Software, maker of Crash Bandicoot.

current job

Andreessen Horowitz
Andreessen Horowitz
Menlo Ventures

Menlo Ventures

Menlo Ventures is a venture capital firm that provides funding for technology companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Software, Venture Capital, Document Management

Location

San Francisco, CA, USA

count Of Investments

634

count Of Exists

165

People

Founders
4
Benjamin Oakes
Benjamin Oakes

Benjamin Oakes

Benjamin Oakes is the Co-Founder, President, and CEO of Scribe Therapeutics.

current job

Scribe Therapeutics
Scribe Therapeutics

organization founded

1

Benjamin Oakes

Brett Staahl
Brett Staahl

Brett Staahl

Brett Staahl is the Co-Founder and VP of Platform at Scribe Therapeutics.

current job

Scribe Therapeutics
Scribe Therapeutics

organization founded

1

Brett Staahl

David F. Savage
David F. Savage

David F. Savage

David Savage is the Co-Founder and Scientific Advisor of Scribe Therapeutics.

current job

Scribe Therapeutics
Scribe Therapeutics

organization founded

1

David F. Savage

Jennifer Doudna
Jennifer Doudna

Jennifer Doudna

Jennifer Doudna is the Chief Science Advisor at Sixth Street. She attended Pomona College and Harvard University.

current job

Sixth Street
Sixth Street

count Of Investments

3

Jennifer Doudna

Employee Profiles
6
David Parrot

David Parrot

CFO

George Manning

George Manning

Controller

Benjamin Oakes

Benjamin Oakes

Co-Founder, President & CEO

David F. Savage

David F. Savage

Co-Founder

Brett Staahl

Brett Staahl

Co-Founder and VP of Platform

Jennifer Doudna

Jennifer Doudna

Co-Founder

Activity

Recent News
6
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month